Download the amazing global Makindo app: ✅ Means NICE/National Guidelines 2026 compliant Android \| Apple

MEDICAL DISCLAIMER: Educational use only. Not for diagnosis or management. See below for full disclaimer.

Heart Failure with preserved and reduced EF ✅

🫀 Heart failure (HF) is a clinical syndrome (symptoms + signs) caused by a structural/functional cardiac problem leading to reduced cardiac output and/or raised filling pressures. 🎯 Exam focus: confirm HF → define the phenotype by EF (HFrEF vs HFpEF) → treat congestion + start disease-modifying therapy early → manage comorbidities and triggers.

🔎 Core definitions (EF-based)

🔻 HFrEF (reduced EF): LVEF ≤40% + clinical HF.
🟠 HFmrEF (mildly reduced EF): LVEF 41–49% + clinical HF.
🟢 HFpEF (preserved EF): LVEF ≥50% + clinical HF and evidence of raised filling pressures/diastolic dysfunction (often LA enlargement, LVH, raised E/e’).
📈 HFimpEF (improved EF): previous LVEF ≤40% that has improved to >40% - continue HFrEF therapy (benefit persists).

🧠 Pathophysiology: why HFrEF and HFpEF behave differently

🔻 HFrEF: primary problem is impaired contractility (often post-MI or dilated cardiomyopathy) → ↓ stroke volume → compensatory SNS/RAAS activation → salt/water retention, vasoconstriction, and adverse remodelling (LV dilatation).
🟢 HFpEF: primary problem is impaired relaxation + increased stiffness (often long-standing HTN, ageing, obesity, diabetes) → normal EF but high filling pressures → pulmonary congestion on exertion, AF susceptibility, and exercise intolerance.
⚠️ Both phenotypes share: congestion, neurohormonal activation, inflammation, and high comorbidity burden - but disease-modifying evidence is strongest in HFrEF.

🧩 Causes of Heart Failure (HF) - exam-friendly table

Cause category	Typical examples	Clues / why it matters (high-yield)
🫀 Ischaemic heart disease (IHD)	Prior MI, chronic CAD, hibernating myocardium	Most common cause of HFrEF in the UK; ECG Q waves/old infarct, angina history, regional wall motion abnormalities on echo → consider revascularisation if appropriate.
📈 Hypertension	Long-standing uncontrolled BP	Pressure overload → LVH → diastolic dysfunction (HFpEF) ± later systolic failure; echo shows concentric LVH/LA enlargement; BP control is disease-modifying for HFpEF trajectory.
🚪 Valvular heart disease	AS, AR, MR, MS	Murmurs + echo severity; AS/HTN = pressure overload, AR/MR = volume overload; valve intervention can reverse symptoms and prevent progression.
🧬 Cardiomyopathies	Dilated (familial/idiopathic), hypertrophic, restrictive	Dilated → HFrEF; hypertrophic/restrictive → often HFpEF physiology; think genetics, myocarditis history, alcohol/chemo; cardiac MRI helps phenotype (fibrosis/infiltration).
⚡ Arrhythmia-related HF	AF (loss of atrial kick), rapid AF, SVT, frequent ectopy; tachycardia-induced cardiomyopathy	Rate/rhythm control can markedly improve EF if tachycardia-driven; always check ECG/Holter in “unexplained” HF or fluctuating symptoms.
🦠 Myocarditis	Viral, autoimmune, post-infective	Often younger patient, chest pain/viral prodrome, troponin rise; MRI shows inflammation; some progress to dilated cardiomyopathy.
🧫 Infiltrative / storage disease	Amyloidosis, sarcoid, haemochromatosis	Often HFpEF pattern + thick “sparkly” myocardium, low-voltage ECG (amyloid), conduction disease; specific therapies exist so don’t miss (MRI + targeted blood tests).
🫁 Pulmonary causes (right HF)	Cor pulmonale (COPD/ILD), pulmonary HTN, chronic thromboembolic disease	Raised JVP, peripheral oedema with relatively “clear” lungs; echo RV strain/pulmonary pressures; treat lung disease and consider pulmonary HTN/CTEPH pathways.
🧱 Pericardial disease	Constrictive pericarditis, tamponade	“HF signs with preserved EF”: raised JVP, hepatomegaly/ascites; tamponade = hypotension + tachycardia + raised JVP; echo is key and treatment is procedural.
🧠 Endocrine / metabolic	Thyrotoxicosis, hypothyroidism, diabetes, severe renal failure	Can precipitate or mimic HF via fluid retention and altered vascular tone; TFTs, HbA1c, renal function are part of standard HF workup.
🩸 High-output states	Severe anaemia, sepsis, AV fistula, pregnancy, beriberi (thiamine deficiency), Paget’s	Warm peripheries, bounding pulse, wide pulse pressure; the heart “can’t keep up” despite high CO - treat the driver (e.g., anaemia/sepsis).
🍷 Toxins / drugs / iatrogenic	Alcohol, cocaine; anthracyclines, trastuzumab; radiotherapy; NSAIDs (fluid retention), some CCBs	Medication history is mandatory; stopping/avoiding offending agents can prevent deterioration; chemo-related cardiomyopathy needs cardio-oncology follow-up.
🧷 Congenital / structural	ASD/VSD, coarctation, complex congenital lesions	May present later with pulmonary HTN/right HF or LV failure; murmurs, fixed split S2, echo diagnosis; specialist congenital heart disease input.

🧠 Teaching pearl: In exams, lead with IHD + hypertension + valve disease first, then add the “missable but treatable” causes (tachycardia-induced cardiomyopathy, myocarditis, amyloid/iron overload, pericardial disease, thyroid disease, high-output states). A great closing line is: “I would also look for triggers (infection, ACS, AF with RVR, PE, anaemia, thyroid disease, drugs like NSAIDs) and treat them in parallel.”

📊 HFrEF vs HFpEF (high-yield comparison table)

Feature	🔻 HFrEF (≤40%)	🟢 HFpEF (≥50%)
Typical patient	More often male; ischaemic heart disease; dilated LV	More often older, female; HTN, obesity, diabetes; AF common
Core mechanism	↓ contractility → ↓ forward flow + remodelling	Stiff LV → ↑ filling pressures (esp. with exertion) despite preserved EF
Echo pattern	Low EF, LV dilatation, global/regional wall motion abnormality	Normal EF, concentric LVH, LA enlargement, diastolic dysfunction indices
Symptoms	Very similar: dyspnoea, orthopnoea/PND, fatigue, reduced exercise tolerance, ankle oedema
Signs	S3, displaced apex, signs of congestion	S4 may be present; often HTN; signs of congestion; AF common
Prognostic levers	Strong mortality-reducing GDMT available	Focus on congestion + comorbidity control; SGLT2 inhibitors reduce HF admissions

🩺 Presentation (OSCE structure)

🫁 Breathlessness: exertional dyspnoea → orthopnoea → PND (ask “how many pillows?”).
💧 Congestion: ankle oedema, weight gain, abdominal distension/ascites, nocturia.
🧠 Low output: fatigue, poor exercise tolerance, dizziness, cool peripheries (advanced).
🎧 Key exam findings: raised JVP, bibasal crackles, pleural effusions, pitting oedema, hepatomegaly, displaced apex, murmurs (valve disease), S3 (HFrEF), AF.

🧪 Investigations (UK exam-friendly “what + why”)

📈 ECG: rarely normal in true HF; look for AF, prior MI, LVH, bundle branch block.
🩸 Natriuretic peptides (BNP/NT-proBNP): ventricular stretch marker; excellent rule-out test if low.
🖼️ CXR: cardiomegaly, upper lobe diversion, Kerley B lines, alveolar oedema, pleural effusions.
🫀 Echocardiography (gold standard): confirms EF phenotype, valves, RV function, pulmonary pressures, pericardium, diastolic indices.
🧪 Bloods to look for causes/complications: FBC, U&E (baseline + drug safety), LFTs, TFTs, HbA1c, lipids, ferritin/TSAT (iron deficiency), troponin if ACS suspected.

🧠 Teaching point: HF symptoms are non-specific. The diagnostic “anchor” is usually raised natriuretic peptide + echo confirmation. Obesity can lower BNP/NT-proBNP (false reassurance), while AF/CKD/age can raise them without HF - interpret in context.

💊 Management principles (applies to all HF phenotypes)

🧯 Treat congestion: loop diuretic for fluid overload (symptom relief; not a mortality drug).
🔍 Find and treat the cause: IHD, HTN, valve disease, tachycardia-induced cardiomyopathy, toxins, myocarditis.
🧩 Fix triggers: infection, ACS, AF with RVR, PE, anaemia, thyrotoxicosis, poor adherence, NSAIDs.
🧑‍⚕️ Educate: daily weights, salt/fluid advice when appropriate, vaccination, exercise/rehab, sick-day rules (esp. diuretics/SGLT2i), when to seek help.

🔻 HFrEF (≤40%): disease-modifying therapy (the “4 pillars”)

✅ HFrEF is where you win lives: combine disease-modifying drugs early (as tolerated), then uptitrate. 🎯 Typical “pillar” set: ACEi/ARB or ARNI + beta-blocker + MRA + SGLT2 inhibitor.

🧱 ACEi (or ARB if intolerant): reduces RAAS-driven remodelling and mortality; monitor BP, creatinine, K⁺.
🧠 Beta-blocker (HF-licensed): bisoprolol/carvedilol/metoprolol succinate; start when euvolaemic; slow uptitration.
🧂 MRA: spironolactone/eplerenone; mortality benefit; monitor K⁺ and renal function closely.
🧪 SGLT2 inhibitor: dapagliflozin/empagliflozin; reduces HF hospitalisation and CV events even without diabetes; watch volume status and genital infections.
💧 Loop diuretic: for congestion (symptom control); adjust to weights and renal function.
➕ Selected add-ons (specialist-led): ARNI switch if symptomatic despite ACEi/ARB; ivabradine (sinus rhythm HR ≥70 despite BB); hydralazine/isosorbide dinitrate if RAAS drugs not tolerated; iron (IV) if deficient; devices (ICD/CRT) based on EF/QRS/LBBB and symptoms.

🟢 HFpEF (≥50%): what actually helps

🧠 HFpEF is often “comorbidity-driven HF”: you improve symptoms and admissions by controlling BP, volume status, AF, ischaemia, obesity, diabetes, sleep apnoea. SGLT2 inhibitors have clear outcome benefit for HFpEF/HFmrEF (especially reducing HF admissions).

💧 Diuretics for congestion: cornerstone for symptom relief (careful with preload dependence).
🩺 Blood pressure optimisation: treat HTN aggressively (reduces LVH and filling pressures).
🫀 AF management: rate/rhythm strategy + anticoagulation when indicated; AF is a major driver of HFpEF decompensation.
🍩 Weight + metabolic health: obesity and insulin resistance worsen diastolic stiffness; weight loss/exercise improves functional capacity.
🧪 SGLT2 inhibitors: recommended option for HFpEF/HFmrEF to reduce HF events (UK appraisal-supported).
🧩 Consider specialist therapies: MRAs/ARNI may help selected patients (benefits vary); decisions usually MDT/heart failure clinic-led.

⚖️ HFrEF vs HFpEF: “what you say in exams”

🎤 HFrEF: “I will start disease-modifying therapy early (4 pillars) and uptitrate to target doses, plus diuretics for congestion.”
🎤 HFpEF: “I will treat congestion with diuretics and aggressively manage comorbidities (HTN, AF, obesity, diabetes), consider SGLT2 inhibitor, and arrange HF clinic follow-up.”

🚨 Acute decompensated HF (quick OSCE line)

🫁 Sit up, oxygen only if hypoxic, monitor, IV access, treat pulmonary oedema (IV loop diuretic ± nitrates if hypertensive), treat trigger (ACS/AF/sepsis), early senior/CCO input if unstable.

📚 References (UK + core)

The content on this website is provided for educational and informational purposes only to support exam preparation (e.g., MLA, MRCP, USMLE) and learning. This is NOT medical advice, diagnosis, treatment, or professional guidance. It does not replace consultation with a qualified healthcare professional, official guidelines (e.g., NICE, GMC, BNF), or supervised clinical practice. Always verify information with current, authoritative sources. Makindo and its contributors accept no liability for any reliance on this content, including errors, omissions, or any resulting harm, loss, or consequences. By using this site, you agree to these terms.